Latham & Watkins (Brussels)

Wesley Lepla

Latham & Watkins (Brussels)
Counsel

Wesley Lepla works as counsel for Latham & Watkins in their Brussels office where he advises on all aspects of Belgian and European competition law, including merger control, cartels, anticompetitive agreements, abuse of a dominant position, and state aid law. He has worked on a range of merger control cases before the European Commission and numerous national authorities and has gained extensive experience in coordinating multijurisdictional merger control notifications and proceedings. Mr. Lepla has represented clients in antitrust proceedings and regularly counsels on state aid, vertical agreements, and the licensing of intellectual property rights. Mr. Lepla is also a research and teaching assistant at the law faculty of the Free University of Brussels (VUB).

Distinctions

Linked authors

Latham & Watkins (Paris)
Latham & Watkins (San Francisco)
Latham & Watkins (Hambourg)
Latham & Watkins (Brussels)
Latham & Watkins (London)

Articles

990 Bulletin

Marilena Nteve, Wesley Lepla, Miranda Cole The EU Court of Justice dismisses the appeals of several manufacturers of medicines against the General Court’s judgment upholding the Commission’s pay-for-delay infringement decision (Lundbeck)

476

On 25 March 2021, the Court of Justice of the European Union (“CJEU”) dismissed the appeals by Lundbeck, Merck KGaA (and Generics UK), Arrow, Alpharma (and Xellia) and Ranbaxy, against the General Court’s (“GC”) judgment upholding the European Commission’s (“Commission”) 2013 pay-for-delay (...)

Miranda Cole, Wesley Lepla The England & Wales Court of Appeal provides guidance regarding the legal test to determine whether pricing is excessive and unfair in the pharmaceutical market (Pfizer / Flynn)

248

The UK Court of Appeal Clarifies the Legal Test for Excessive Pricing* Under Article 102 of the Treaty on the Functioning of the European Union (“TFEU”), an undertaking may abuse its dominant position by “directly or indirectly imposing unfair purchase or selling prices”. The UK Court of (...)

Spyridon Goulielmos, Wesley Lepla, Miranda Cole The England & Wales Court of Appeal provides guidance on the legal test for excessive and unfair pricing after finding that an undertaking is charged unfairly high prices for phenytoin sodium capsules (Pfizer / Flynn)

223

Under Article 102 of the Treaty on the Functioning of the European Union (“TFEU”), an undertaking may abuse its dominant position by “directly or indirectly imposing unfair purchase or selling prices”. The UK Court of Appeal recently provided guidance regarding the legal test to determine (...)

Statistics


990
Total visits

247.5
Number of readings per contribution

4
Number of contributions

Author's ranking
2337th
In number of contributions
4527th
In number of visits
6083th
In average number of visits
Send a message